Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
STUDY17022 First in Human, Phase 1/1b, Open label, Multicenter Study of Bifunctional EGFR/TGF ß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR Driven Advanced Solid Tumors The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors. Study Information
STUDY25167 A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas To assess whether the combination of doxorubicin and pembrolizumab will improve progression free survival in UPS and related poorly differentiated sarcomas relative to doxorubicin alone. Study Information
STUDY25493 Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma: a Single Institution Phase II Trial The primary objective of this study is to assess the safety of preoperative 5-day HFRT as measured by the rates of major wound complications occurring within 120 days of surgery. Study Information